Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jin Suk Park *Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yasemin Kaygusuz *Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carson KenumCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lan HeCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mohamed I GatieDevelopmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8500-5609
Xueqian ZhuangCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7012-3223
Roshan SharmaSingle-Cell Analytics Innovation Lab, Alan and Sandra Gerry Metastasis and Tumor Microenvironment Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9886-009X
Ronan ChalignéSingle-Cell Analytics Innovation Lab, Alan and Sandra Gerry Metastasis and Tumor Microenvironment Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4332-3291
Umesh K BhanotPathology Core Facility, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6656-1239
Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6820-5083
Tuomas TammelaCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3675-6961
Anna-Katerina HadjantonakisDevelopmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7580-5124
Charles M RudinMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5204-3465
Joan MassaguéCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. massaguj@mskcc.org.ORCID 0000-0001-9324-8408
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
The Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2M
The TGF Beta Signaling Pathway in Development and CancerR35CA252978 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JOAN MASSAGUE · 2020 to 2026
$7.3M
Novel therapeutic development for small cell lung cancerR35CA263816 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Charles M. Rudin · 2021 to 2026
$6.3M
Mechanisms driving cell fate specification and morphogenesis in the blastocystR01HD094868 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI ANNA-KATERINA HADJANTONAKIS · 2018 to 2026
$4.2M
Morphogenesis of mammalian gut endodermR01DK084391 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI HADJANTONAKIS, ANNA-KATERINA · 2009 to 2018
$4.1M
Targeting plasticity in lung cancerR01CA270116 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Tuomas Tammela · 2023 to 2026
Plasticity transitions during carcinoma progression generate fetal-like progenitor states with metastatic capacity. How these progenitors emerge and persist during tumor progression remains unclear. Here, we elucidate a process that drives the emergence of SOX2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
L1CAM signaling through planar cell polarity drives SOX2 expression and lung adenocarcinoma metastasis. · full record | OpenQuestion